Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes
NCT03631654 · University of Maryland, Baltimore · PHASE4 · withdrawn · last registry update 2024-12-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to obtain funding” | – | Registry record, University of Maryland, Baltimore |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCN4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-12-05Phase 3 first posted: Gødstrup Hospital, atenolol + Metoprolol tartrate (NCT07268170)
- 2025-10-30Also stopped (terminated): Tulane University School of Medicine, dronedarone 400 mg Oral Tablet + Placebo (NCT04704050)
- 2025-10-16Results posted on the registry: Tulane University School of Medicine, dronedarone 400 mg Oral Tablet + Placebo (NCT04704050)
- 2025-06-08Results posted on the registry: Phillip Levy, Ivabradine + Placebo (NCT03168529)
- 2025-02-06Results posted on the registry: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-02-06Also stopped (terminated): Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision